TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7623725

Group type: EXPERIMENTAL
Intervention: Pre-radiotherapy chemotherapy (vincristine, procarbazine, methotrexate)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Reduced dose radiotherapy (25 Gy to the craniospinal axis)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Standard radiotherapy (35 Gy to the craniospinal axis)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Post-radiotherapy chemotherapy (vincristine and CCNU for high risk children)
Number of subjects: 364
Study: 2259867

Group type: EXPERIMENTAL
Intervention: Amikacin 11 mg/kg bw
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Amikacin 15 mg/kg bw
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Amikacin once daily dosing
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Amikacin serum concentration monitoring
Number of subjects: 29
Study: 7377745

Group type: EXPERIMENTAL
Intervention: Sulfadiazine (SD) 500 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfadiazine (SD) 250 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfamethoxazole (SM) 1000 mg twice daily
Number of subjects: 0
Study: 31991511

Group type: EXPERIMENTAL
Intervention: Vibegron 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vibegron 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vibegron 50 mg and 100 mg
Number of subjects: 0
Study: 30132051

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing (RP)
Number of subjects: 49

Group type: COMPARATOR
Intervention: No patellar resurfacing (non-RP)
Number of subjects: 49
Study: 27641003

Group type: EXPERIMENTAL
Intervention: Deferiprone 8.3 mg kg‐1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Deferiprone 16.7 mg kg‐1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Deferiprone 33.3 mg kg‐1
Number of subjects: 18
Study: 25982057

Group type: EXPERIMENTAL
Intervention: Focused Attention Meditation (FAM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open Monitoring Meditation (OMM)
Number of subjects: 0
Study: 24083367

Group type: EXPERIMENTAL
Intervention: Computer-based Bayesian algorithm
Number of subjects: 65

Group type: COMPARATOR
Intervention: Manual nurse decision process
Number of subjects: 65
Study: 21244439

Group type: EXPERIMENTAL
Intervention: Kudzu extract (total isoflavone dose of 750 mg/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19961042

Group type: EXPERIMENTAL
Intervention: eperisone 300 mg/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: eperisone 150 mg/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 18190257

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) twice-daily therapy
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) once-daily therapy
Number of subjects: 228
Study: 15045702

Group type: EXPERIMENTAL
Intervention: Hepatic lipase deficiency patients
Number of subjects: 8
Study: 11254910

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg twice daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 9462248

Group type: EXPERIMENTAL
Intervention: TAS (whole blood)
Number of subjects: 48
Study: 8187257

Group type: EXPERIMENTAL
Intervention: 40% oxygen during TIVAK
Number of subjects: 140

Group type: COMPARATOR
Intervention: Room air during TIVAK
Number of subjects: 140
Study: 3122575

Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotropin (150 U administered hourly)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone (75 ng/kg administered hourly)
Number of subjects: 10
Study: 30618880

Group type: EXPERIMENTAL
Intervention: Mutual support group
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Psycho-education group
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 201
Study: 27046320

Group type: EXPERIMENTAL
Intervention: Varenicline (12-week open-label phase followed by a 40-week randomized, placebo-controlled phase)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (40-week randomized, placebo-controlled phase)
Number of subjects: 65
Study: 25761501

Group type: EXPERIMENTAL
Intervention: Before treatment for intestinal parasites
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: After successful antiparasitic treatment
Number of subjects: 21
Study: 23050945

Group type: EXPERIMENTAL
Intervention: Glucosamine (Artrox®) 625 mg twice daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (Vitamineral® multivitamin tablet)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Atorvastatin group
Number of subjects: 34
Study: 20649492

Group type: EXPERIMENTAL
Intervention: Sensory electrical stimulation (ES)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control sham intervention
Number of subjects: 6
Study: 17979080

Group type: EXPERIMENTAL
Intervention: Aquatic physical exercises over a 12-week programme
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 28
Study: 15908764

Group type: EXPERIMENTAL
Intervention: rabeprazole 10 mg once daily
Number of subjects: 84

Group type: COMPARATOR
Intervention: ranitidine 300 mg once daily
Number of subjects: 84
Study: 12479049

Group type: EXPERIMENTAL
Intervention: External RF hyperthermia (ERFH) combined with alpha 1-adrenergic receptor blocker Terazosin for 12 weeks
Number of subjects: 136

Group type: COMPARATOR
Intervention: External RF hyperthermia (ERFH)
Number of subjects: 136
Study: 9656040

Group type: EXPERIMENTAL
Intervention: Instillation of 5‐mL bolus of normal saline before suctioning
Number of subjects: 29

Group type: COMPARATOR
Intervention: No instillation of normal saline before suctioning (Control)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Instillation of normal saline before suctioning
Number of subjects: 29
Study: 8134215

Group type: EXPERIMENTAL
Intervention: Pediatric Home Care (PHC)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 219
Study: 2777428

Group type: EXPERIMENTAL
Intervention: Liquid-filled capsules (20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Slow-release tablets (20 mg)
Number of subjects: 10
Study: 1120220

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 0
Study: 31345559

Group type: EXPERIMENTAL
Intervention: propofol + dexmedetomidine 0.4 μg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: propofol + ketamine 0.4 mg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: propofol + saline (control group)
Number of subjects: 120
Study: 30517575

Group type: EXPERIMENTAL
Intervention: 30 minutes compression (G30)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: 60 minutes compression (G60)
Number of subjects: 303
Study: 25941053

Group type: EXPERIMENTAL
Intervention: Intervention (mobile-team outreach)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not exposed to the intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brothel-based female sex workers
Number of subjects: 0
Study: 24142540

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 50
Study: 22913464

Group type: EXPERIMENTAL
Intervention: Pilot trial involving qualitative interviews with service providers and participants (children and parents)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with four dentists and 17 dental team members
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Face-to-face interviews with four parents and children, and five telephone interviews with parents
Number of subjects: 21
Study: 21039673

Group type: EXPERIMENTAL
Intervention: Prucalopride
Number of subjects: 1455
Study: 17657860

Group type: EXPERIMENTAL
Intervention: Distal protection device (PercuSurge GuardWire; GW)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no GW protection)
Number of subjects: 112
Study: 16277179

Group type: EXPERIMENTAL
Intervention: Fluorescence cystoscopy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard white light endoscopy
Number of subjects: 109
Study: 12411094

Group type: EXPERIMENTAL
Intervention: Video viewing plus education with talk
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Video viewing
Number of subjects: 648

Group type: COMPARATOR
Intervention: Control group (A)
Number of subjects: 648
Study: 9707653

Group type: EXPERIMENTAL
Intervention: 250 micrograms of intradermal (ID) capsaicin (CAP) to the volar forearm with skin temperature fixed at 36 degrees C (36 ID)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 250 micrograms ID CAP with varying skin temperature (VT ID)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 250 microliters of 1% CAP patch placed on the skin at 36 degrees C (Topical)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 micrograms ID CAP in the volar forearm or foot dorsum
Number of subjects: 12
Study: 7851554

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Laparoscopic ultrasound
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of laparoscopy and laparoscopic ultrasound
Number of subjects: 40
Study: 2693432

Group type: EXPERIMENTAL
Intervention: Short course tobramycin and cefoperazone (discontinued at day four)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Tobramycin plus cefoperazone (continued for up to 26 days)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Tobramycin plus mezlocillin (continued for up to 26 days)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Short course tobramycin therapy
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Cefoperazone (after day four)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Cefoperazone (not associated with vitamin K)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Granulocytopenia recovery
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Initial episodes of fever related to documented infections
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Bacteraemia, pneumonia or Gram-positive aerobic or Pseudomonas aeruginosa infections
Number of subjects: 195
Study: 352710

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide lactam, methyloxazepam and oxazepam
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: N-desmethyl-diazepam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Alcohol
Number of subjects: 40
Study: 31848765

Group type: EXPERIMENTAL
Intervention: Telephone-delivered mindfulness training (MT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Health coaching (HC)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both MT and HC
Number of subjects: 42
Study: 30600526

Group type: EXPERIMENTAL
Intervention: Intranasal sufentanil (0.4 μg/kg)
Number of subjects: 144

Group type: COMPARATOR
Intervention: IV-only multimodal analgesics (control group)
Number of subjects: 144
Study: 27930926

Group type: EXPERIMENTAL
Intervention: Naltrexone with prolonged exposure (PE)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Naltrexone without prolonged exposure (PE)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Placebo with prolonged exposure (PE)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Placebo without prolonged exposure (PE)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Supportive counseling (BRENDA) alone
Number of subjects: 165
Study: 25383689

Group type: EXPERIMENTAL
Intervention: Mindfulness-based Kindness Curriculum (KC)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 23163747

Group type: EXPERIMENTAL
Intervention: Dominance strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prestige strategy
Number of subjects: 0
Study: 21319897

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) intervention, 8-week group during pregnancy and 3 individual booster sessions postpartum
Number of subjects: 217

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) intervention
Number of subjects: 217
Study: 19843674

Group type: EXPERIMENTAL
Intervention: Highest quartile of energy intake
Number of subjects: 29170

Group type: EXPERIMENTAL
Intervention: Highest quartile of energy intake with BMI and physical activity included
Number of subjects: 29170

Group type: COMPARATOR
Intervention: Energy intake from a FFQ administered approximately five years after entry
Number of subjects: 29170

Group type: EXPERIMENTAL
Intervention: High energy intake over three 4-year periods
Number of subjects: 29170
Study: 17985062

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation with oligosaccharides (1.3 g/250 ml) for 12 weeks
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no oligosaccharides)
Number of subjects: 74
Study: 15271773

Group type: EXPERIMENTAL
Intervention: Fibromyalgia
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Chronic low back pain (CLBP)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Ankylosing spondylitis
Number of subjects: 291
Study: 12611198

Group type: EXPERIMENTAL
Intervention: Morphine plus metoclopramide
Number of subjects: 132

Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Morphine > 60 mg/d
Number of subjects: 132
Study: 9658729

Group type: EXPERIMENTAL
Intervention: Nadroparin (95 IU/kg bid for a minimum of 7 days)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Nadroparin (home treatment)
Number of subjects: 71
Study: 8018909

Group type: EXPERIMENTAL
Intervention: Intermittent cyclic regimen of intermediate-dose methotrexate (MTX) plus 6-mercaptopurine (6MP)
Number of subjects: 811

Group type: COMPARATOR
Intervention: Conventional continuous administration of low dose of MTX plus 6MP
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Three-drug induction therapy consisting of vincristine (VCR), prednisone (PDN), and L-asparaginase (L-ASP)
Number of subjects: 811

Group type: COMPARATOR
Intervention: Two-drug therapy consisting of VCR and PDN
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Regimen with cranial irradiation
Number of subjects: 811

Group type: COMPARATOR
Intervention: Regimen without cranial irradiation
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Cyclic administration of intermediate-dose MTX plus 6MP as maintenance therapy
Number of subjects: 811
Study: 2465774

Group type: EXPERIMENTAL
Intervention: Mucin-based artificial saliva (Saliva Orthana)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-mucin base
Number of subjects: 30

Group type: COMPARATOR
Intervention: Water
Number of subjects: 30
Study: 4129562

Group type: EXPERIMENTAL
Intervention: 200 mg dose of Delta 1 testololactone
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: 1000 mg dose of Delta 1 testololactone
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: 2000 mg dose of Delta 1 testololactone
Number of subjects: 362
Study: 30312190

Group type: EXPERIMENTAL
Intervention: Online 12-week walking intervention
Number of subjects: 91

Group type: COMPARATOR
Intervention: Active control group (pedometer only)
Number of subjects: 91
Study: 30957445

Group type: EXPERIMENTAL
Intervention: Acupuncture with elongated needle at Zhibian (BL 54) and Shuidao (ST 28), provided once every two days for 2 months.
Number of subjects: 66

Group type: COMPARATOR
Intervention: Acupuncture with filiform needle at Zhibian (BL 54) and Shuidao (ST 28), provided once every two days for 2 months.
Number of subjects: 66
Study: 26988739

Group type: EXPERIMENTAL
Intervention: Flapless approach (test group)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Flap approach (control group)
Number of subjects: 35
Study: 26005163

Group type: EXPERIMENTAL
Intervention: Rabies + JE-Accelerated
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rabies + JE-Standard
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rabies-Standard
Number of subjects: 0

Group type: COMPARATOR
Intervention: JE-Standard
Number of subjects: 0
Study: 24103072

Group type: EXPERIMENTAL
Intervention: More intensive belatacept immunosuppression (MI)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Less intensive belatacept immunosuppression (LI)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 304
Study: 21641360

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 260
Study: 19114905

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (HT) of 33 degrees C for 24 hours
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normothermia (core temperature kept <38 degrees C)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (HT) of 33 degrees C
Number of subjects: 70
Study: 16275171

Group type: EXPERIMENTAL
Intervention: Longitudinal quantitative chest radiography
Number of subjects: 0
Study: 15310445

Group type: COMPARATOR
Intervention: Midline incision (Group A)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Para‐median incision (Group B)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 11771634

Group type: EXPERIMENTAL
Intervention: Mortality salience
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 9053491

Group type: EXPERIMENTAL
Intervention: GM-CSF (5 microg/kg/d for up to 21 days)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 102

Group type: COMPARATOR
Intervention: GM-CSF and Placebo
Number of subjects: 102
Study: 8498662

Group type: EXPERIMENTAL
Intervention: Intravenous alfentanil (PCA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Epidural alfentanil (PCA)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Comparison of SpO2 effects
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Severe desaturation episodes
Number of subjects: 32
Study: 3031226

Group type: EXPERIMENTAL
Intervention: Chest radiation therapy (4,800 rad in a split-course scheme)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Chemotherapy without interruption (maintenance chemotherapy with cyclophosphamide and VP-16)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Preinduction treatment volume or postinduction reduced tumor volume (radiation treatment portals based on tumor extent)
Number of subjects: 494
Study: 30243424

Group type: EXPERIMENTAL
Intervention: Mecamylamine (10 mg/day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 26499920

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant
Number of subjects: 117

Group type: COMPARATOR
Intervention: Systemic therapy with oral corticosteroids and immunosuppression
Number of subjects: 117
Study: 24410433

Group type: EXPERIMENTAL
Intervention: Intervention group (Prevention plus, Stage 1 treatment)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 23866098

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts, >3 servings/week
Number of subjects: 7216

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with nuts, >3 servings/week
Number of subjects: 7216

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 7216
Study: 20655125

Group type: EXPERIMENTAL
Intervention: Framing group emphasizing externalities of the uninsured
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: Framing group raising racial and ethnic disparities
Number of subjects: 1203

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1203
Study: 18681988

Group type: EXPERIMENTAL
Intervention: 100 mg L-theanine + 50 mg caffeine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 50 mg caffeine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 15930487

Group type: EXPERIMENTAL
Intervention: Soy-based meal replacement (MR)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Milk-based meal replacement (MR)
Number of subjects: 90
Study: 12842055

Group type: EXPERIMENTAL
Intervention: Nurse continence advisor therapy
Number of subjects: 145

Group type: COMPARATOR
Intervention: Urogynaecologist treatment
Number of subjects: 145
Study: 11067788

Group type: EXPERIMENTAL
Intervention: Magnesium (30 mmol/d Magnosolv‐Granulat)
Number of subjects: 50
Study: 8780282

Group type: EXPERIMENTAL
Intervention: Ondansetron (1, 4, or 8 mg intravenously before induction of anesthesia)
Number of subjects: 873

Group type: COMPARATOR
Intervention: Placebo (intravenously before induction of anesthesia)
Number of subjects: 873
Study: 1621434

Group type: EXPERIMENTAL
Intervention: IgG-anticardiolipin-antibodies in patients with cerebral and peripheral artery disease (group C)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: IgG-anticardiolipin-antibodies in patients with peripheral artery disease only (group B)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: IgM-anticardiolipin-antibodies in all groups
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (group D)
Number of subjects: 123
Study: 6517243

Group type: EXPERIMENTAL
Intervention: General anaesthesia with thiopental sodium, succinylcholine, alcuronium and halothane
Number of subjects: 74

Group type: COMPARATOR
Intervention: Catheter epidural anaesthesia (CEA) with bupivacaine
Number of subjects: 74
Study: 30943128

Group type: EXPERIMENTAL
Intervention: Intervention (school-based program)
Number of subjects: 654

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 654
Study: 30021592

Group type: EXPERIMENTAL
Intervention: Group-based lifestyle intervention consisting of 15 sessions over 12 months
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Community-based activities (walking groups, kitchen garden training, yoga training)
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Peer leader (PL) training and ongoing support
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Extracurricular contacts with PLs
Number of subjects: 1007
Study: 25942012

Group type: EXPERIMENTAL
Intervention: 7-minute circuit training (CT-7)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 14-minute circuit training (CT-14)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Non-training control group (C)
Number of subjects: 96
Study: 25185683

Group type: EXPERIMENTAL
Intervention: Chromoendoscopy-guided endomicroscopy (CGE)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Conventional colonoscopy (CC)
Number of subjects: 162